Written by Shreena Chotai on Friday 8th January 2021
OPEN Health are proud to publish their 2020 rare disease yearbook. This presents highlights of articles and webinars we developed last year with the aim of improving outcomes for people living with rare disease. Whilst progress continues to be made, there remains significant unmet need within the rare disease community and we are fully committed to playing our part in improving rapid and sustained access to new therapies and wider support services.
Our CEO Rob Barker provides his thoughts on our continued investment in rare disease:
‘OPEN Health is very proud of our established experience in this space and will remain committed to supporting our clients improve the lives of many people living with rare disease. It’s an exciting time with many therapies moving through clinical development that have the potential to transform patients lives. Our broad capabilities, coupled with our extensive experience and investment, make us the ideal Global partner to help deliver positive change in rare disease’.
Our investment is led by Gavin Jones, Global Advisor, Rare Diseases, and he had the following reflections on 2020 and our activities throughout the year:
‘It was obviously a very difficult year for the rare disease community with concerns over the virus, isolation through shielding and worries for charities over funding. However, there were also some positives with far greater levels of connectivity amongst the community through a virtual world. It meant that we were privileged to be able to work with many more members of the patient advocacy community and hear first-hand the challenges they face and what can be done to improve lives. We look forward to what 2021 brings and partnering again to deliver better outcomes’
OPEN Health commit to publishing our rare disease yearbook on a six monthly basis to maintain positive pressure on all of our teams to constructively take the conversation forward in rare disease.
If you would like to understand more about our commitment, capabilities and experience in rare disease please contact Gavin.